Some in the drug industry insist that a small percentage of 340B hospitals actually help low-income patients. A new comparative study of 340B DSH hospitals and non-340B hospital sets the record straight. The study found that: As a percentage of total patient care costs, 340B disproportionate share hospitals provide nearly twice as much care as non-340B hospitals – 41.9 … [Read more...]
Study: 340B Hospitals Provide Nearly Twice as Much Care to the Poor as Other Hospitals
Also reportedly provide nearly 30 percent more uncompensated careJune 3, 2015—340B disproportionate share hospitals provide nearly twice as much care to poor patients as non-340B hospitals and bear a much higher burden of uncompensated care, a new study has found. … [Read more...]
Generic Drug Prices Dropping More Slowly, AARP Says
Era of consistent declines may be ending, it warnsJune 2, 2015—Although average retail prices for common generic drugs continue falling, the percentage decline in 2013 for such drugs was its smallest in seven years, according to a new study from AARP Public Policy Institute. … [Read more...]
CMS Proposes Rule Addressing 340B Medicaid Managed Care Drugs
It would be up to MCOs to develop preventive measuresMay 29, 2015—The Centers for Medicare & Medicaid Services proposes to make Medicaid managed care organizations – as opposed to 340B covered entities or state Medicaid agencies – responsible for establishing procedures to prevent 340B duplicate discounts in the Medicaid MCO context. … [Read more...]
MedPAC Publishes 340B Program Overview
Also plans to address 340B in June report to CongressMay 29, 2015—Congressional Medicare advisers have released a 34-page, standalone descriptive paper about the 340B drug discount program, less than a month before they give Congress a broader Medicare policy report that will address 340B among other issues. … [Read more...]
340B Manufacturer Civil Monetary Penalty Proposed Regulation Slated for July
Publication timeline appears in government's latest unified regulatory agendaMay 22, 2015— A 340B program proposed regulation establishing civil monetary penalties for drugmakers that intentionally overcharge and setting standards for calculating 340B ceiling prices is penciled in for July, according to the latest edition of the federal government's regulatory agenda. Another proposed regulation creating a mandatory and binding 340B administrative … [Read more...]
House Panel Passes Cures Initiative Minus 340B Language
Hospital groups lobbied hard to exclude last-minute amendmentMay 21, 2015—The House Energy & Commerce Committee passed the 21st Century Cures Act today without adding language to it related to 340B drug discounts. … [Read more...]